Cargando…
Diabetic ketoacidosis after the treatment of anaphylaxis
SUMMARY: Anaphylaxis is a rapidly progressive potentially lethal condition, and epinephrine is the most crucial medication in its treatment. In this study, we present a case of diabetic ketoacidosis in a young woman that was precipitated by the administration of epinephrine to treat anaphylaxis. Thi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422262/ https://www.ncbi.nlm.nih.gov/pubmed/35979815 http://dx.doi.org/10.1530/EDM-21-0171 |
_version_ | 1784777773960658944 |
---|---|
author | Brenner, Daniel S Kleinman, Keith Manzo, Amy Bembea, Melania M Cooke, David W |
author_facet | Brenner, Daniel S Kleinman, Keith Manzo, Amy Bembea, Melania M Cooke, David W |
author_sort | Brenner, Daniel S |
collection | PubMed |
description | SUMMARY: Anaphylaxis is a rapidly progressive potentially lethal condition, and epinephrine is the most crucial medication in its treatment. In this study, we present a case of diabetic ketoacidosis in a young woman that was precipitated by the administration of epinephrine to treat anaphylaxis. This patient had diabetes mellitus and poor glycemic control and developed ketoacidosis despite having evidence of ongoing endogenous insulin production and having been treated with exogenous long-acting insulin less than 24 h prior to the event. This is a rare, serious, adverse side effect of life-saving medication. This report demonstrates that the risk of diabetic ketoacidosis should be considered when administering epinephrine to patients with diabetes, even in the absence of complete insulin deficiency. LEARNING POINTS: Epinephrine directly suppresses insulin secretion, stimulates lipolysis, and causes ketone body generation. High-dose catecholamine administration can cause unexpected diabetic ketoacidosis in patients with risk factors. Early administration of insulin may not protect patients from developing ketoacidosis in the setting of high-dose catecholamine administration. |
format | Online Article Text |
id | pubmed-9422262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-94222622022-08-29 Diabetic ketoacidosis after the treatment of anaphylaxis Brenner, Daniel S Kleinman, Keith Manzo, Amy Bembea, Melania M Cooke, David W Endocrinol Diabetes Metab Case Rep Unusual Effects of Medical Treatment SUMMARY: Anaphylaxis is a rapidly progressive potentially lethal condition, and epinephrine is the most crucial medication in its treatment. In this study, we present a case of diabetic ketoacidosis in a young woman that was precipitated by the administration of epinephrine to treat anaphylaxis. This patient had diabetes mellitus and poor glycemic control and developed ketoacidosis despite having evidence of ongoing endogenous insulin production and having been treated with exogenous long-acting insulin less than 24 h prior to the event. This is a rare, serious, adverse side effect of life-saving medication. This report demonstrates that the risk of diabetic ketoacidosis should be considered when administering epinephrine to patients with diabetes, even in the absence of complete insulin deficiency. LEARNING POINTS: Epinephrine directly suppresses insulin secretion, stimulates lipolysis, and causes ketone body generation. High-dose catecholamine administration can cause unexpected diabetic ketoacidosis in patients with risk factors. Early administration of insulin may not protect patients from developing ketoacidosis in the setting of high-dose catecholamine administration. Bioscientifica Ltd 2022-04-21 /pmc/articles/PMC9422262/ /pubmed/35979815 http://dx.doi.org/10.1530/EDM-21-0171 Text en © The authors https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Unusual Effects of Medical Treatment Brenner, Daniel S Kleinman, Keith Manzo, Amy Bembea, Melania M Cooke, David W Diabetic ketoacidosis after the treatment of anaphylaxis |
title | Diabetic ketoacidosis after the treatment of anaphylaxis |
title_full | Diabetic ketoacidosis after the treatment of anaphylaxis |
title_fullStr | Diabetic ketoacidosis after the treatment of anaphylaxis |
title_full_unstemmed | Diabetic ketoacidosis after the treatment of anaphylaxis |
title_short | Diabetic ketoacidosis after the treatment of anaphylaxis |
title_sort | diabetic ketoacidosis after the treatment of anaphylaxis |
topic | Unusual Effects of Medical Treatment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422262/ https://www.ncbi.nlm.nih.gov/pubmed/35979815 http://dx.doi.org/10.1530/EDM-21-0171 |
work_keys_str_mv | AT brennerdaniels diabeticketoacidosisafterthetreatmentofanaphylaxis AT kleinmankeith diabeticketoacidosisafterthetreatmentofanaphylaxis AT manzoamy diabeticketoacidosisafterthetreatmentofanaphylaxis AT bembeamelaniam diabeticketoacidosisafterthetreatmentofanaphylaxis AT cookedavidw diabeticketoacidosisafterthetreatmentofanaphylaxis |